Melanoma Drugs Market Report 2026

Melanoma Drugs Market Overview

• Melanoma Drugs market size has reached to $10.15 billion in 2025 • Expected to grow to $17.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Rising Incidence Of Melanoma In Males Fuels Growth In The Melanoma Drug Market • Market Trend: Breakthrough Cell-Based Immunotherapies Accelerate Treatment Advances In Advanced Melanoma • North America was the largest region in 2025.

What Is Covered Under Melanoma Drugs Market?

Melanoma drug refers to a drug used for the medication of skin cancer that develops in the cells that produce melanin, the pigment responsible for the color of the skin, hair, and eyes. Melanoma drugs are used to treat melanoma that aims to target and inhibit the growth and spread of melanoma cells in the body. The main therapies of melanoma drugs are chemotherapy, immunotherapy, and targeted therapy. Chemotherapy is a medical treatment that involves the use of drugs to destroy or inhibit the growth of cancer cells. It is one of the primary treatment options for cancer and is typically used in combination with other therapies such as surgery and radiation therapy. The melanoma drugs are used for treating superficial spreading melanoma, lentigo maligna, acral lentiginous melanoma, and nodular melanoma in hospitals, outpatient oncologist clinics, and others.

What Is The Melanoma Drugs Market Growth Forecast?

The melanoma drugs market size is expected to see rapid growth in the next few years. It will grow to $17.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to advances in precision medicine, development of combination therapies, rising geriatric population, increased funding for melanoma research, integration of ai in drug discovery. Major trends in the forecast period include personalized melanoma therapy development, targeted immunotherapy advancements, combination treatment approaches, early detection and diagnostic innovations, orphan and rare melanoma treatment focus.

Global Melanoma Drugs Market Segmentation

1) By Therapy: Chemotherapy, Immunotherapy, Targeted Therapy 2) By Disease Type: Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma, Nodular Melanoma 3) By Application: Hospitals, Outpatient Oncologist Clinics, Other Applications Subsegments: 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Topoisomerase Inhibitors 2) By Immunotherapy: Checkpoint Inhibitors, Interleukin Therapy, Oncolytic Virus Therapy, Cancer Vaccines 3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, Immune Modulators, Other Targeted Agents

What Is The Driver Of The Melanoma Drugs Market?

The increase in the incidence of melanoma in males is expected to propel the growth of the melanoma drug market over the coming years. Melanoma is a type of skin cancer developed in the cells (melanocytes) that regulate the pigment in the skin. Melanoma drugs are medications used to treat melanoma, and these drugs aim to target and inhibit the growth and spread of melanoma cells in the body. Hence the increasing incidence of melanoma will increase the demand for melanoma drugs market. For instance, in 2023, according to the report published by the American Cancer Society, Inc., a US-based nationwide voluntary health organization dedicated to eliminating cancer, new male individuals suffering from melanoma in the United States increased to 58,120 in 2023 from 57,180 in 2022. Therefore, an increase in incidences of melanoma in males is driving the growth of the melanoma drug industry.

Key Players In The Global Melanoma Drugs Market

Major companies operating in the melanoma drugs market are Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Merck & Co. Inc., Aduro Biotech Inc., Seagen Inc., OncoSec Medical Incorporated, Regeneron Pharmaceuticals Inc., Iovance Biotherapeutics, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Daiichi Sankyo Company Limited, Gilead Sciences, MacroGenics Inc., Kyowa Kirin Co. Ltd., Fortress Biotech Inc., OSE Immunotherapeutics, Vical Incorporated, Almirall S.A.

Global Melanoma Drugs Market Trends and Insights

Major companies operating in the melanoma drugs market are focusing on advancing next-generation cell-based immunotherapies, such as tumor-infiltrating lymphocyte (TIL) therapies, to enhance treatment efficacy for patients with advanced or unresectable melanoma. TIL therapy involves extracting and expanding a patient’s own tumor-infiltrating immune cells and reinfusing them to boost the body’s ability to recognize and eliminate cancer cells, offering a promising option for individuals who have limited response to existing systemic immunotherapies. For instance, in February 2024, Iovance Biotherapeutics, a U.S.-based biotechnology company, received FDA approval for AMTAGVI (lifileucel), the first-ever tumor-infiltrating lymphocyte (TIL) therapy approved for advanced melanoma. According to the FDA, the therapy demonstrated an overall response rate (ORR) of 31.5%, including 5.6% complete responses, in heavily pretreated patients with unresectable or metastatic melanoma. Designed to deliver a personalized, one-time cellular immunotherapy, AMTAGVI provides a significant therapeutic breakthrough and expands clinical options for melanoma patients with limited treatment alternatives.

What Are Latest Mergers And Acquisitions In The Melanoma Drugs Market?

In May 2025, Sun Pharmaceutical Industries Limited, an India-based provider of specialty generics, dermatology products, and onco-dermatology therapies, acquired Checkpoint Therapeutics for an undisclosed amount. With this acquisition, Sun Pharma aims to strengthen its immuno-oncology portfolio by adding a first-in-class anti–PD-L1 therapy and expanding its capabilities in advanced skin cancer treatment. Checkpoint Therapeutics is a U.S.-based developer of novel immunotherapies and targeted oncology medicines, including treatments for cutaneous squamous cell carcinoma and other solid tumors.

Regional Insights

North America was the largest region in the melanoma drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Melanoma Drugs Market?

The melanoma drug market consists of sales of pembrolizumab, nivolumab, vemurafenib, avelumab, and dabrafenib with trametinib drugs used for the treatment of melanoma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Melanoma Drugs Market Report 2026?

The melanoma drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.